Motivation: Although genome-wide association studies (GWAS) have deepened our understanding of the genetic architecture of complex traits, the mechanistic links that underlie how genetic variants cause complex traits remains elusive. To advance our understanding of the underlying mechanistic links, various consortia have collected a vast volume of genomic data that enable us to investigate the role that genetic variants play in gene expression regulation. Recently, a collaborative mixed model (CoMM) [42] was proposed to jointly interrogate genome on complex traits by integrating both the GWAS dataset and the expression quantitative trait loci (eQTL) dataset. Although CoMM is a powerful approach that leverages regulatory information while accounting for the uncertainty in using an eQTL dataset, it requires individual-level GWAS data and cannot fully make use of widely available GWAS summary statistics. Therefore, statistically efficient methods that leverages transcriptome information using only summary statistics information from GWAS data are required. Results: In this study, we propose a novel probabilistic model, CoMM-S 2 , to examine the mechanistic role that genetic variants play, by using only GWAS summary statistics instead of individual-level GWAS data. Similar to CoMM which uses individual-level GWAS data, CoMM-S 2 combines two models: the first model examines the relationship between gene expression and genotype, while the second model examines the relationship between the phenotype and the predicted gene expression from the first model. Distinct from CoMM, CoMM-S 2 requires only GWAS summary statistics. Using both simulation studies and real data analysis, we demonstrate that even though CoMM-S 2 utilizes GWAS summary statistics, it has comparable performance as CoMM, which uses individual-level GWAS data.
Introduction
Over the last decade, genome-wide association studies (GWAS) have achieved remarkable success in identifying genetic susceptibility variants for a variety of complex traits/diseases [39] .
However, the biology of how genetic variants affect complex traits remains unclear. Recent expression quantitative trait loci (eQTL) studies indicate that regulatory information play an important role in mediating the complex traits/diseases [26] . Measured comprehensive cellular traits can serve as reference data and provide investigators with an avenue to examine the role that genetic variants play in gene expression regulation. For example, the Genotype-Tissue Expression (GTEx) Project [23] has provided DNA sequencing data (about 12.5 million variants) from 449 individuals and collected gene-expression measurements of 44 tissues from these individuals; the number of subjects increases to 620 in over 48 tissues in the recent V7 release. Although the sample sizes of these reference datasets are limited, they provide an important avenue for one to study how genetic variants regulate human gene expression in different tissues.
In the absence of identical cohorts in eQTL and GWAS datasets, various authors have proposed statistical methods that allow one to leverage regulatory information on the cellular mechanisms in a GWAS analysis. These methods can be broadly grouped into two categories.
The first group consists of methods that require the use of individual-level GWAS data, and include methods such as PrediXcan [10] and CoMM [42] . Because methods in this category require the availability of all individual-level genotype and phenotype data, their application can be complicated by restrictions on data sharing and storage. In contrast to the first group of methods that utilize individual-level data, the second group of methods uses GWAS summary statistics; for example one could apply the second group of methods to GWAS results that are publicly available from GWAS repositories, such as the NHGRI-EBI GWAS Catalog [4] . Examples of these methods include TWAS [13] , S-PrediXcan [1] , and UTMOST [17] . Among these methods, TWAS and S-PrediXcan use transcriptome data from a single tissue while UTMOST can be applied to cross-tissue analysis. Generally, TWAStype methods (PrediXcan, S-PrediXcan, TWAS and UTMOST) proceed with three steps.
First, the expression reference panel is used to fit predictive models for each gene using genetic variants in the vicinity of a gene. Next, levels of gene expression for the individuals in the GWAS data are predicted using these models. Finally, associations between the predicted expression levels and the complex trait are examined by simple linear regressions.
Consequently, TWAS-type methods do no account for the uncertainty associated with the first step. In contrast, CoMM accounts for the uncertainty by combining the three steps in 3 a unified probabilistic framework.
Compared with methods using individual-level GWAS data, methods using GWAS summary statistics face an additional difficulty: the summary statistics do not contain any information of linkage disequilibrium (LD), which plays an important role in prioritizing variants in GWAS. TWAS used an imputation method to impute the expression-trait association statistics directly from GWAS summary statistics [13] while S-PrediXcan derived a test statistic using pre-calculated weights to expression and a reference panel to estimate correlation (LD) among cis-variants. To make use of summary statistics rigorously, it is important to develop a probabilistic model. [16] first proposed an approximated distribution for z-scores in CAVIAR. Later, [45] formalized this distribution by introducing a regression with summary statistics (RSS) likelihood in a Bayesian framework and they further showed that the difference between the RSS log-likelihood and the one from individual-level data was constant. Although the approximated RSS-type distribution has been extended in several works including RSS-E [46] and REMI [18] , both of these works including RSS are designed for one-sample studies. In the analysis using two different samples, such as PrediXcan, TWAS and CoMM, the questions become how to combine a RSS distribution for GWAS summary statistics with that for eQTL data.
To overcome the limitation of not accounting for uncertainty and further extend CoMM using GWAS summary statistics, we propose a probabilistic model, a Collaborative Mixed Models for GWAS summary statistics -CoMM-S 2 . Unlike TWAS and S-PrediXcan, our method accounts for the uncertainty in the 'imputed' gene expression. The key idea is to build a joint probabilistic model for GWAS summary statistics and individual-level eQTL data, and use the 1KG data as a reference panel to estimate LD. We has also developed an efficient variational Bayesian expectation-maximization accelerated using parameter expansion (PX-VBEM), where the calibrated evidence lower bound is used to conduct likelihood ratio tests for genome-wide gene associations with complex traits/diseases. We illustrate the performance of CoMM-S 2 with extensive simulation studies and real data applications of 10 traits in NFBC1966 dataset and summary statistics from 14 traits/diseases. The results demonstrate that CoMM-S 2 performs better than competing methods.
Methods

Notation
Suppose that we have an individual-level eQTL dataset D 1 = {Y, W 1 } that consists of n 1 samples, g genes and m genetic variants, and where Y ∈ R n 1 ×g is a matrix of gene expression and W 1 ∈ R n 1 ×m is a genotype matrix. In addition, we have the GWAS summary statistics
where γ ∈ R m and s ∈ R m are the effect sizes and standard errors from the single-variant analysis for all genetic variants. We further assume that the individual-level GWAS data corresponding to D 2 has the phenotype vector z ∈ R n 2 ×1 and the centered genotype matrix W 2 ∈ R n 2 ×m . The sample sizes of D 1 and D 2 are generally distinct, with D 1 having a smaller sample size (≈ 10 2 ) compared to the sample size of D 2 (≈ 10 4 ∼ 5×10 5 ).
We will examine gene expression levels for each gene individually. Let y j , the j-th column of Y, be the gene expression level of the j-th gene and let W 1j be a genotype matrix containing its nearby genetic variants (within either 50 kb upstream of the transcription start site or 50 kb downstream of the transcription end site, in this study), respectively.
We standardize the genotype data W 1j = [w 1j1 , . . . , w 1jm j ] ∈ R n 1 ×m j to mean zero and unit variance. Correspondingly, summary statistics for genetic variants using the centered genotype (W 2j ) within the j-th gene is { γ j , s j }, where γ j ∈ R m j , s j ∈ R m j , and m j is the number of variants corresponding to the j-th gene. Denote S j = diag( s j ) a diagonal matrix for the j-th gene and R j ∈ R m j ×m j the estimated correlation among genetic variants within the j-th gene. 5 
Model
We first model the relationship in the eQTL data using linear regression
where γ j = [γ j1 , . . . , γ jm j ] T is an m j × 1 vector of genetic effects on the gene expression, e ∼ N (0, σ 2 e I) is an n 1 × 1 vector of independent random noises for the gene expression levels, X ∈ R n 1 ×q are the design matrix for covariates including intercept, and β is a q × 1 vector of the corresponding effect sizes for covariates. Similar to CoMM [42] , the relationship between the phenotype z and genotype W 2j nearby the j-th gene can be modeled as
where e 2 ∼ N (0, σ 2 e2 I) is an n 2 ×1 vector of independent error associated with the phenotype. Here, α j represents the effects of gene expression of gene j on the phenotype, due to genotype.
Assume that individual-level data {z, W 2 } is inaccessible, but the summary statistics { γ, s} from the univariate linear regression are available. It can be shown that the distribution of γ j can be approximated by [45] 
provided that sample size n 2 to generate these summary statistics is large and the trait is highly polygenic (i.e., the squared correlation coefficient between the trait and each genetic variant is close to zero). We further assume the prior distribution for γ j is a Gaussian,
which is widely used in genetics [44] . Taking γ j as the latent variable, the complete data likelihood can be written as
6 where θ = {σ 2 γ j , σ 2 e , α j , β} is the collection of model parameters. By integrating out latent variable γ j , the marginal likelihood is
Algorithm
We require a computationally efficient algorithm that is capable of fitting model (5) when the signal-noise-ratio is low. A standard expectation-maximization (EM) algorithm in not ideal for this purpose due to the slow convergence; a Newton-Raphson algorithm is also not ideal because it can be unstable because of the non-negative constraint on variance components. Additionally, a standard EM algorithm involves the inversion of R j , which may cause numerical failure as R j is estimated from a small reference panel. Therefore, we develop a variational Bayesian (VB) EM algorithm [3] accelerated by parameter expansion [22] , namely, PX-VBEM. First, the original model (1) can be expanded as follows
where τ ∈ R is the expanded parameter, the likelihood for summary statistics (3) and the prior remain the same, and model parameters become θ = {σ 2 γ j , σ 2 e , α j , β, τ }. Next, we sketch the variational Bayesian EM algorithm for the expanded model (7). Given a variational posterior distribution q(γ j ), it is easy to verify that the marginal likelihood can be decomposed into two components, the evidence lower bound (ELBO) and the KL divergence,
where
Note that L(q) is the ELBO of the marginal likelihood, and KL(q||p) is Kullback-Leibler (KL) divergence between two distributions and satisfies KL(q||p) ≥ 0, with the equality holding if, and only if, the variational posterior probability (q) and the true posterior probability (p) are equal. Similar to the EM algorithm, we can maximize the ELBO L(q) by optimizing with respect to q that is equivalent to minimizing the KL divergence [2] . To make the evaluation of the lower bound computationally efficient, we use the mean-field theory [27] and assume that q(γ j ) can be factorized as
This is the only assumption that we make using variational inference. This factorization (10) is used as an approximation for the posterior distribution p(γ j |X, W 1j , y j , γ j , S j , R j ; θ). In the VB E-step, given the hidden variables γ ji , i = k, the terms with γ jk have a quadratic form, where i and k are indices for the i-th and the k-th genetic variants, respectively. Thus, the variational posterior distribution of γ jk is a Gaussian distribution N (u jk , v 2 jk ). The details of derivation for the updating formula of mean u j = [u j1 , . . . , u jm j ] T and standard 
where y * j = y j − Xβ is the vector of residuals after removing the fixed effects, denotes the element-wise multiplication of two vectors, and diag(A) denotes a vector whose elements are the diagonal entries of the square matrix A. The corresponding PX-VBEM algorithm is summarized as Algorithm 1 in the supplementary document.
Reference panel
The CoMM-S 2 uses marginal effect sizes and their standard errors to construct probabilistic modeling for summary statistics from GWAS. Using summary-level data, we do not have any information for correlations among SNPs (i.e., LD, denoted as R j ). Here, we choose to use 1KG samples as a reference panel. We first calculate the empirical correlation matrix
, where w jk is the genotype vector for the k-th genetic variant within the j-th gene. To make the estimated correlation matrix positive definite, we applied a simple shrinkage estimator [32] to obtain R j as 3 Statistical Inference
Evaluate association between a a complex trait/disease and a gene
We propose the following statistical test to formally examine the association between a a complex trait/disease and a gene:
A likelihood ratio test (LRT) statistic for the j-th gene is given by
whereθ ML 0 andθ ML are vectors of parameter estimates that are obtained by maximizing the marginal likelihood, under the null hypothesis H 0 and under the alternative hypothesis H A , respectively. Using standard asymptotic theory [38] , the test statistics Λ j asymptotically follows the χ 2 df=1 under the null. As discussed in Section 2.3, to overcome the intractability of maximizing the marginal likelihood, we utilize a (PX)-VBEM algorithm where we maximize the ELBO, instead of the marginal likelihood, to obtain parameter estimatesθ 0 andθ. Earlier applications demonstrate that (PX)-VBEM produces practically useful and accurate posterior mean estimates [3, 8, 43, 34] (i.e.θ 0 andθ). While it might seem reasonable to use the estimated posterior distribution from maximizing the ELBO to directly approximate the marginal likelihood in Equation 13 , it is well-known that the (PX)-VBEM typically identifies posterior distributions that underestimate the marginal variances [40, 36] . Consequently, this is not a feasible approach. Instead of using the estimated posterior distribution as a proxy for the marginal likelihood in Equation 13 , under the assumption that the posterior means of interest are well-estimated by (PX)-VBEM for all the parameters of interest (i.e.θ 0 andθ estimated using (PX)-VBEM are well-estimated), we plug-in our estimates from the (PX)-VBEM algorithm into the marginal likelihood in Equation 13 to construct the test statistic.
We term the resulting likelihood with plug-in estimates from the (PX)-VBEM algorithm a calibrated ELBO and provide more details in the next section. Briefly, the calibrated ELBO is used as a proxy to the marginal likelihood in the test statistics. Our numerical studies show that a test constructed using the calibrated ELBO works well.
Calibrated ELBO
We postulate that the ELBO can be calibrated using the form from the (PX)-EM algorithm by plugging the posterior mean estimates and parameter estimates from (PX)-VBEM, which can be used as a proxy to marginal log-likelihood. Here we describe the procedures to calibrate the ELBO in detail. The marginal log-likelihood from the PX-EM algorithm for model (8) can be written as follows
where u j and Σ j are the joint posterior mean and posterior variance for latent variable γ j , and Σ j is expressed as
Note that we explicitly express the marginal log-likelihood (14) from the PX-EM algorithm that depends on the posterior mean, u j , and parameter estimates, θ, as the posterior variance Σ j is fully characterized by model parameters θ. Thus, we first fit the data using the PX-VBEM (Algorithm 1 in the supplementary document). Then, we re-evaluate the marginal log-likelihood from the (PX)-EM algorithm by plugging the posterior mean estimates and parameter estimates θ = {σ 2 γ j , σ 2 e , α g , β, τ } from the PX-VBEM algorithm as equation (14). Given the fact that the posterior means from (PX)-VBEM are accurate enough, the calibrated ELBO is close to the marginal log-likelihood. In Section 4, we conducted simulation studies to show that the marginal log-likelihood evaluated under the proposed calibrated procedure approximates well to that from (PX)-EM algorithms.
Simulations
Simulation settings
We conducted simulation studies to demonstrate that (a) CoMM-S 2 has comparable performance as CoMM (Section 4.2.1) and that (b) CoMM-S 2 generally performs as well or better than competing methods that also utilize summary statistics (Section 4.2.2). For (b), we compared the performance of CoMM-S 2 with S-PrediXcan, with both ridge regression and Enet [47] , denoted as S-PrediXcan:Ridge and S-PrediXcan:Enet, respectively.
We considered the following simulation settings to evaluate the performance of CoMM-S 2 .
We assumed sample sizes of n 1 = 400, n 2 = 5, 000, and n 3 = 400, which are the sample sizes for the transcriptome dataset, GWAS dataset and the reference panel dataset, respectively.
To generate genotype data, we first generated a data matrix using a multivariate normal distribution N (0, Σ(ρ)), where Σ(ρ) is an auto-regressive correlation structure with ρ = 0.2, 0.5 and 0.8, representing weak, moderate and strong LD, respectively. We then generated minor allele frequencies from a uniform distribution U(0.05, 0.5) and categorized the data matrix into trinary variables taking values 0, 1, 2 using these minor allele frequencies and assuming Hardy-Weinberg equilibrium. All three genotype matrices, W 1j , W 2j and W ref j (where W 1j , W 2j are as defined in Section 2.1, and W ref j is a genotype data from a reference panel as described in Section 2.4) are generated in this manner.
To generate eQTL data from genotype data, we considered different cellular-level heritability levels (h 2 C ) and sparsity levels, which are parameters that describe the genetic architecture of gene expression [41] . The cellular-level heritability (h 2 C ) represents the proportion of variance of the eQTL that can be explained by genotype, while sparsity represents the proportion of genetic variants that are associated with the gene expression. For a given cellular-level heritability h 2 C , a larger number of genetic variants that are associated with gene expression levels implies a smaller genetic influence on gene expression, per genetic variant. We generated eQTL data assuming y j = W 1j γ j + e 1 , where e 1 ∼ N (0, σ 2 e 1 I n 1 ), and the non-zero γ j were generated assuming γ jk ∼ πN (0, σ 2 γ j ) + (1 − π)δ 0 , π is the eQTL sparsity level, δ 0 denotes a Dirac delta mass function at 0, and k is the index for genetic variants within gene j. σ 2 e 1 and σ 2 γ j were chosen to correspond to cellular-level heritability levels h 2 C of 0.01, 0.05, or 0.09, which are close to the median gene expression heritability estimates computed across all genes [29] . We considered different eQTL sparsity levels of 0.1, 0.2 ,0.3, 0.4 and 0.5, where a sparsity level of 0.2 indicates that only 20% of the SNPs have non zero effects (i.e. 20% of the γ j 's are non-zero).
We generated a complex trait assuming z = α j W 2j γ j + e 2 . We assumed 100 local genetic variants (cis-SNPs). e 2 was chosen such that the organismal-level heritability level,
is controlled at h 2 T ∈ {0, 0.001, 0.002, 0.003}. A organismal-level heritability h 2 T = 0 corresponds to the null hypothesis that the gene has no association with the organismal-level trait. 
Simulation results
CoMM-S 2 and CoMM have comparable performance
We first compared the LRT test statistics from both CoMM-S 2 and ComMM. We used 1,000 simulation replicates to compare the LRT test statistics of the two methods As shown in Next, we compared the calibrated ELBO as described in Section 3.2 with the marginal log-likelihood evaluated the using EM algorithm. Here, we consider the reference panel to be the GWAS data itself, which enables the evaluation of the marginal log-likelihood from EM algorithm. As shown in Figure S1 demonstrates that the calibrated ELBO is very similar to the marginal log-likelihood.
In the real data analysis of the NFBC1966 dataset (Section 5.2), we observed that a small proportion of test statistics from CoMM are degenerate zero. To better understand this phenomenon, we conducted additional simulations described in Supplementary Section 4.3. As shown in Figures S8 (a) 
Real Data Analysis
We applied CoMM-S 2 to two data sets, individual-level data NFBC1966 [30] and summary statistics from 14 traits (see Tables S1 and S2), with the transcriptome data from GEU-VADIS Project [21] and Genotype-Tissue Expression (GTEx) Project [23] , respectively. The NFBC dataset consists of information on ten quantitative traits. The ten quantitative traits include body mass index (BMI), systolic blood pressure (SysBP), diastolic blood pressure (DiaBP), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol 16 (LDL-C), triglycerides (TG), total cholesterol (TC), insulin levels, glucose levels and Creactive protein (CRP). We also collected fourteen traits/diseases from multiple GWAS consortia including six diseases traits and eight BMI-related traits. Diseases traits are Alzheimer's disease (AD), coronary artery disease (CAD), autism spectrum disorder (ASD), schizophrenia (SCZ), type 2 diabetes (T2D), myocardial infarction (MI). There are eight summary statistics for BMI-related traits from 2017 GIANT Gene-Physical Activity Interaction Meta-analysis [12] including two sex-combined traits, BMI for physically active individuals 
Analysis of NFBC1966 datatset
As we have individual-level data for NFBC1966 dataset, we then applied both CoMM and CoMM-S 2 using individual-level data and summary statistics, respectively. We first analyzed the individual-level data from NFBC1966 with the transcriptome data from GEUVADIS using CoMM. The results from CoMM can be taken as a benchmark as it uses individuallevel data. We then conducted single-variant analysis for NFBC1966 dataset to generate summary statistics. Finally, we applied CoMM-S 2 using summary statistics from NFBC1966 dataset. As CoMM-S 2 uses a reference panel to give estimates for LD, R j , we applied two different choices of reference panel, namely, 400 subsamples from NFBC1966 and European samples from 1KG [7] . The scatter plots of LRT test statistics for CoMM against CoMM-S 2 using 400 subsamples from NFBC1966 are given in Figure 4 and the one using 1KG samples as reference data is shown in Figure S24 in the supplementary document. When we used the subsamples as the reference panel (in Figure 4) , we notice that the test statistics from CoMM-S 2 are close to their counterpart with slope around 1 and R 2 ranging from 0.91 to 0.99. When the reference panel becomes 1KG as shown in Figure S13 , one can observe that the test statistics in the null region (Λ g < 20.84 ≡ p-value ¿ 5 × 10 −6 ) from both CoMM and CoMM-S 2 are roughly around the line with slope equals to 1. The test statistics in the non-null region (Λ g ≥ 20.84 ≡ p-value ≤ 5 × 10 −6 ) are inflated. This is primarily due to the reference panel we used to estimate correlations. When we applied sub-samples from NFBC1966 as reference panel data, this difference essentially disappeared. The reason for this phenomenon could be that despite that NFBC1966 dataset is a Finn's study from Europe, Finnish samples was shown its genetic distinctness in previous studies [31] .Although this genetic discrepancy for Finnish population, we found that the inflation only appears in the non-null regions, which makes the use of 1KG as reference panel practically useful. Note that in these comparisons, we removed genes with cellular heritability less than 0.01 as the test statistics for tiny cellular heritability using CoMM is not reliable. The use of cutoff here is to make fair comparisons between CoMM and CoMM-S 2 as test statistics of CoMM degenerates to zero when cellular heritability is small (see Figure S8 ). In practice, we do not require this limit as CoMM-S 2 also works in tiny cellular heritability regions. To verify the phenomenon of degeneration, we compared CoMM-S 2 and CoMM with RL-SKAT [33] for genes with cellular heritability less than 0.01 as shown in Figure S14 . The result is consistent with the simulation results from both Section 4.2 and our previous work [42] . Figure 4 : The scatter plot of LRT statistics for CoMM-IS vs CoMM, with transcriptiome data from GTEx tissue Adipose Subcutaneous, GWAS data from NFBC1966 dataset, and reference panel data from 400 subsamples of NFBC1966 dataset. We remove the points with cellular heritability less than 0.001.
Analysis of 14 traits
We performed the analysis for 14 GWAS summary statistics with transcriptome data from GTEx and the detailed information of these 14 traits are shown in Tables S1 and S2. Specifically, we applied CoMM-S 2 together with S-PrediXcan (both Enet and Ridge) to examine the associations between each pair of a gene and the complex trait. We display qq-plots for each trait across all tissues in Figure S15 . After completing the analysis using three approaches, we conducted genomic control for each trait-tissue pair. The genome-wide significant threshold is set to be 5 × 10 −6 based on Bonferroni correction.
The results indicate that CoMM-S 2 identified more significant associations than S-PrediXcan.The analysis for each individual summary statistics together with the transcriptome data for a tissue can be done around 20 min on a Linux platform with 2.6 GHz intel Xeon CPU E5-2690 with 30 720 KB cache and 96 GB RAM (0nly 6∼7 GB RAM used) on 24 cores.
CoMM-S 2 is primarily developed to identify the associations between genes and complex traits using summary statistics. It is not only power in the region that cellular heritability is relatively large, but can also identify associations in the weak cellular heritability region.
We show both the number of unique genes passing genome-significance level across different tissues and the number of genes reported in the previous studies in Table 1 while the total number of genes identified across 48 tissues using CoMM-S 2 and S-PrediXcan (both Enet and Ridge) is shown in Table S3 . For example, as shown in Table 1 , CoMM-S 2 identified 199 unique genes across all tissues and 37 of them were previously reported in NHGRI-EBI GWAS Catalog [4] for AD while S-PrediXcan (both Enet and Ridge) identified 95 and 108 genes with 24 and 28 genes reported before, respectively. However, CoMM-S 2 identified 4,614 genes in total across 48 tissues while S-PrediXcan (both Enet and Ridge) identified only 398 and 664 genes in total, respectively, which indicates that there are more overlapped genes identified by CoMM-S 2 but the genes identified by S-PrediXcan (both Enet and Ridge) are more or less unique across tissues. Specifically, in GTEx adipose subcutaneous tissue, CoMM-S 2 identified seven genes in band 2q14.3, 12 genes in band 8p21.2, 14 genes in bands 11q12.1 and 11q12.2, 13 genes in bands 11q14.1 and 11q14.2, and 51 genes in band 19q13.32. Among them, 24 genes were reported to be associated with AD in previous studies [5, 6, 24, 9, 28, 19] . However, S-PrediXcan can only identify six of these 24 genes.
Note that 18 out of these 24 genes have h 2 C > 1% and among the six genes having h 2 C ≤ 1%, S-PrediXcan (both Enet and Ridge) only identified one gene and none, respectively. In addition, gene BIN1 was identified among all 48 tissues and cellular heritability for gene BIN1 are larger than 10% in eight tissues, e.g., h 2 C = 13.5% in brain cerebellum, h 2 C = 13.7% in brain cortex, h 2 C = 23.3% in esophagus muscularis mucosa, and highest in pancreas with h 2 C = 30.6%. Hence, the associations between gene BIN1 and AD in tissues with large h 2 C are more likely to be causal, where targeting BIN1 might present novel AD therapy [35] .
Gene PTK2B has largest cellular heritability in tissue brain cerebellum (h 2 C = 32.4%), which was one of most significant genes associated with AD in a meta-analysis [20] . In a mouse model, overexpression of PTK2B improved the behavioral and molecular phenotype of a 20 strain of AD-linked mutated mice [11] . Gene CLU has the largest cellular heritability in the adrenal gland tissue(h 2 C = 22.7%), which has been found to be related to cholesterol synthesis, transport, uptake or metabolism in AD that links between cholesterol and AD pathogenesis [15] .
For CAD, CoMM-S 2 identified 117 unique genes across all tissues and 15 of them were previously reported in NHGRI-EBI GWAS Catalog [4] while S-PrediXcan (both Enet and Ridge) identified 71 and 73 genes with 11 and 11 genes reported before, respectively. However, CoMM-S 2 identified 2,067 genes in total across all tissues while S-PrediXcan (both Enet and Ridge) identified only 109 and 184 genes in total, respectively. Specifically, in the artery aorta tissue, CoMM-S 2 identified two genes in band 2q33.2, one gene in band 3q22.3, three genes in band 6p24.1, two genes in band 6q25.3, eight genes in band 9p21.3, four genes in bands 12q24.11 and 12q24.12, six genes in band 13q34, seven genes in band 15q25.1, and five genes in band 19p13.2. Among them, nine genes were reported to be associated with CAD in previous studies [14, 25, 37] . However, S-PrediXcan can only identify two of these nine genes. Gene NBEAL1 was identified to be genome-wide significant in eleven tissues.
Among these eleven tissues, h 2 C = 13.9% in artery aorta, h 2 C = 9.3% in artery tibial, and h 2 C = 10.2% in pituitary are relative large, in which gene NBEAL1 is likely to be causal for CAD.
The results of the identified genes for all 14 traits across tissues together with their corresponding test statistics and p-values for CoMM-S 2 , S-PrediXcan (both Enet and Ridge)
can be found in excel tables in the supplementary files.
Conclusion
In this article, we have developed a collaborative mixed model using summary statistics from GWAS to account for uncertainty in transcriptome imputation. We examined the 21 The number of significant genes identified across the tissues at the significant level (5×10 −6 ) for each method. In this table, the same genes identified across the tissues are only counted once. The number within the parenthesis denoted the number of genes reported in NHGRI-EBI GWAS Catalog [4] .
relationship between CoMM and CoMM-S 2 . Our numerical results show that CoMM-S 2 has comparable performance as CoMM. CoMM-S 2 has several advantages over CoMM. First, CoMM-S 2 can be computationally more efficient than CoMM when applied to GWAS that have large sample sizes. This is because CoMM-S 2 is applied to summary statistics, which is faster to compute in large sample sizes, while CoMM is applied to individual-level data.
Second, through empirical studies, we show that CoMM-S 2 has better performance when the cellular heritability is low. However, CoMM-S 2 is not without limitations. First, CoMM-S 2 cannot be utilized in a cross-tissue analysis, for example as illustrated in [17] . Furthermore, CoMM-S 2 cannot differentiate whether the identified genes are simply associated with the complex traits or if they are real causal effects. These are avenues for further research.
